Cantor Fitzgerald analyst Li Watsek initiated coverage of Ideaya Biosciences with an Overweight rating.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences management to meet with Oppenheimer
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- Ideaya Biosciences price target lowered to $52 from $54 at Wedbush
- Ideaya Biosciences should be bought on weakness, says Citi
- Ideaya Biosciences price target raised to $48 from $47 at Goldman Sachs
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue